Loading patent…
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsCandace S. Johnson, Donald L. Trump
Estimating the term…
This invention relates to combination chemotherapy, particularly involving vitamin D or a derivative thereof. In one aspect, the invention provides a method of killing a cell by first administering to the cell vitamin D (or a derivative) and subsequently administering to the cell a cytotoxic agent. Where this strategy is applied to an intact tumor, the present invention provides a method of retarding the growth of the tumor by first administering vitamin D (or a derivative) to the tumor and subsequently administering the cytotoxic agent. A further aspect of the invention concerns a method of treating prostate cancer within a patient by co-administration of vitamin D (or a derivative) and a glucocorticoid to the patient. In yet a further aspect, the invention provides an improved method of treating a patient with vitamin-D involving the adjunctive administration of zoledronate.
A method of killing a cell within a patient comprising the steps of (a) first administering to a cell within the patient vitamin D or a derivative thereof and (b) subsequently administering at least one cytotoxic agent to the cell, wherein the cell is susceptible to said steps (a) and (b).
A method of retarding the growth of a tumor within a patient comprising the steps of (a) first administering to the tumor within the patient a vitamin D or a derivative thereof and (b) subsequently administering to the tumor at least one cytotoxic agent, wherein the cell is susceptible to said steps (a) and (b).
A method of treating a human patient with vitamin D or a derivative thereof, wherein the patient has a condition responsive to vitamin D and a cytotoxic agent, comprising the steps of (a) first administering to the patient vitamin D or a derivative thereof and (b) subsequently administering to the patient at least one cytotoxic agent, wherein the dose of the vitamin D or a derivative thereof exceeds 1 μg/day.
A method of treating prostate cancer within a patient in need of such treatment comprising adjunctively administering vitamin D or a derivative thereof and a glucocorticoid to the patient.
Dependencies are inferred from the claim text.